Scholarlink

<p>Sudden cardiac death (SCD) is a leading cause of mortality in heart failure (HF), yet its incidence, mechanisms, and predictors in heart failure with preserved ejection fraction (HFpEF) remain poorly characterized. We conducted a prospective study of 2331 patients hospitalized for decompensated HF, stratifying them into HFpEF (n = 754), HF with mid-range ejection fraction (HFmrEF, n = 369), and HF with reduced ejection fraction (HFrEF, n = 1208). Over a median 25-month follow-up, 298 patients (12.8%) experienced SCD. HFpEF patients had the lowest SCD incidence (5.9%) compared to HFmrEF (13.8%) and HFrEF (16.7%) (<i>p</i> &lt; 0.01). Asystole predominated in HFpEF SCD cases (52.9%), whereas ventricular tachyarrhythmias dominated in HFmrEF and HFrEF. In multivariate competing risk analysis, NYHA class III (cause-specific hazard ratio [csHR] 2.04, 95% CI 1.20–3.45, <i>p</i> &lt; 0.01; subdistribution hazard ratio [sHR] 1.56, 95% CI 1.16–1.96, <i>p</i> = 0.01) and prolonged QTc interval &gt; 480&#xa0;ms (csHR 1.63, 95% CI 1.03–2.55, <i>p</i> = 0.01; sHR 1.57, 95% CI 1.04–2.38, <i>p</i> = 0.03) independently predicted SCD in patients with HFpEF. These findings reveal distinct SCD patterns in HFpEF and underscore the need for phenotype-specific risk stratification and prevention strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Distinct mortality patterns and sudden cardiac death mechanisms in heart failure with a preserved ejection fraction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月23日

查看全文
  • Yoshihiro Sobue,
  • Eiichi Watanabe,
  • Masanobu Yanase,
  • Hideo Izawa

摘要

Sudden cardiac death (SCD) is a leading cause of mortality in heart failure (HF), yet its incidence, mechanisms, and predictors in heart failure with preserved ejection fraction (HFpEF) remain poorly characterized. We conducted a prospective study of 2331 patients hospitalized for decompensated HF, stratifying them into HFpEF (n = 754), HF with mid-range ejection fraction (HFmrEF, n = 369), and HF with reduced ejection fraction (HFrEF, n = 1208). Over a median 25-month follow-up, 298 patients (12.8%) experienced SCD. HFpEF patients had the lowest SCD incidence (5.9%) compared to HFmrEF (13.8%) and HFrEF (16.7%) (p < 0.01). Asystole predominated in HFpEF SCD cases (52.9%), whereas ventricular tachyarrhythmias dominated in HFmrEF and HFrEF. In multivariate competing risk analysis, NYHA class III (cause-specific hazard ratio [csHR] 2.04, 95% CI 1.20–3.45, p < 0.01; subdistribution hazard ratio [sHR] 1.56, 95% CI 1.16–1.96, p = 0.01) and prolonged QTc interval > 480 ms (csHR 1.63, 95% CI 1.03–2.55, p = 0.01; sHR 1.57, 95% CI 1.04–2.38, p = 0.03) independently predicted SCD in patients with HFpEF. These findings reveal distinct SCD patterns in HFpEF and underscore the need for phenotype-specific risk stratification and prevention strategies.